Outcomes of hospitalized hematologic oncology patients receiving rapid response system activation for acute deterioration

Benjamin Gershkovich 1,13*, Shannon M. Fernando 1,2, Brent Herritt 1, Lana A. Castellucci 3,4,5, Bram Rochwerg 6,7, Laveena Munshi 8, Sangeeta Mehta 8, Andrew J. E. Seely 1,3,9, Daniel I. McIsaac 3,4,10, Alexandre Tran 3,9, Peter M. Reardon 1,2, Peter Tanuseputro 3,4,11 and Kwadwo Kyeremanteng 1,4,11,12

Abstract

Background: Patients with hematologic malignancies who are admitted to hospital are at increased risk of deterioration and death. Rapid response systems (RRSs) respond to hospitalized patients who clinically deteriorate. We sought to describe the characteristics and outcomes of hematologic oncology inpatients requiring rapid response system (RRS) activation, and to determine the prognostic accuracy of the SIRS and qSOFA criteria for in-hospital mortality of hematologic oncology patients with suspected infection.

Methods: We used registry data from two hospitals within The Ottawa Hospital network, between 2012 and 2016. Consecutive hematologic oncology inpatients who experienced activation of the RRS were included in the study. Data was gathered at the time of RRS activation and assessment. The primary outcome was in-hospital mortality. Logistical regression was used to evaluate for predictors of in-hospital mortality.

Results: We included 401 patients during the study period. In-hospital mortality for all included patients was 41.9% (168 patients), and 145 patients (45%) were admitted to ICU following RRS activation. Among patients with suspected infection at the time of RRS activation, Systemic Inflammatory Response Syndrome (SIRS) criteria had a sensitivity of 86.9% (95% CI 80.9–91.6) and a specificity of 38.2% (95% CI 31.9–44.8) for predicting in-hospital mortality, while Quick Sequential Organ Failure Assessment (qSOFA) criteria had a sensitivity of 61.9% (95% CI 54.1–69.3) and a specificity of 91.4% (95% CI 87.1–94.7). Factors associated with increased in-hospital mortality included transfer to ICU after RRS activation (adjusted odds ratio [OR] 3.56, 95% CI 2.12–5.97) and a higher number of RRS activations (OR 2.45, 95% CI 1.63–3.69). Factors associated with improved survival included active malignancy treatment at the time of RRS activation (OR 0.54, 95% CI 0.34–0.86) and longer hospital length of stay (OR 0.78, 95% CI 0.70–0.87).

Conclusions: Hematologic oncology inpatients requiring RRS activation have high rates of subsequent ICU admission and mortality. ICU admission and higher number of RRS activations are associated with increased risk of death, while active cancer treatment and longer hospital stay are associated with lower risk of mortality. Clinicians should consider these factors in risk-stratifying these patients during RRS assessment.

Keywords: Critical care, Malignancy, Mortality, Chemotherapy, Hematology, Sepsis
Background

Hematologic oncology patients admitted to hospital are at high risk of short-term deterioration, due to the nature of their underlying disease processes as well as the chemotherapeutic regimens that they receive [1]. Common complications that lead to clinical deterioration, ICU admission, and/or death include infection, organ-specific toxicities related to chemotherapy, and sequelae of the malignancies themselves, such as tumor-lysis syndrome, leukostasis, or bleeding [2–5].

In an attempt to mitigate the adverse outcomes associated with in-hospital deterioration, rapid response systems (RRSs) have been widely implemented internationally [6]. These teams consist of multi-disciplinary groups of health care providers who respond to in-hospital emergencies and provide acute management, transfer patients to higher level of care settings, or assist with goals-of-care discussions and palliation [7, 8]. The use of RRSs has been associated with lower rates of in-hospital mortality and cardiac arrest, lower rates of readmission to ICU following ICU discharge, and earlier initiation of goals-of-care discussions and facilitation of end-of-life care [9–16].

With respect to the potential causes of deterioration among hematologic oncology inpatients, community-acquired and nosocomial infections are common and account for significant morbidity and mortality [17–19]. Risk stratification of patients with suspected infection is extremely valuable in early initiation of treatment, escalation of care, and evaluation of goals of care. Several tools, including the SIRS criteria [20] and qSOFA score [21], may be used to risk-stratify patients with suspected infection. The use of these risk-stratification tools among inpatients with suspected infection who require RRS activation has been described previously [22, 23]; however, there is a paucity of data with respect to the use of these tools in this specific population.

The outcomes of hematologic oncology patients admitted to the ICU have been described previously [24–28]. A recent retrospective cohort study of 1097 ICU patients with hematologic malignancies reported 28-day, 3-month, and 1-year survival rates of 56%, 48%, and 38% respectively [29]. However, very few previous studies have examined whether or not these outcome data can be extrapolated upstream of ICU admission to patients who deteriorate in-hospital. Taheri et al. [30] recently performed a retrospective analysis of 126 hematologic oncology patients who were assessed by a critical care outreach team and found that a diagnosis of sepsis was associated with an increased risk of mortality for those admitted to ICU. Additionally, several studies have examined early versus late ICU admission among hematologic oncology patients and have consistently found correlations between delayed ICU admission and increased mortality [31–33]. RRS implementation may result in earlier ICU admission for appropriately selected hematologic oncology and hematopoietic cell transplant (HCT) patients, leading to lower mortality rates [34–36].

We sought to examine the outcomes of hospitalized hematologic oncology patients who experience RRS activation for deterioration and to determine the factors that are independently associated with in-hospital mortality. Finally, given the high prevalence of infection and infectious complications among this population, we aimed to examine the prognostic accuracy of the SIRS criteria and the qSOFA criteria for prediction of in-hospital mortality among hematologic oncology patients with suspected infection.

Methods

Study design, setting, and subjects

Ethics approval was obtained from The Ottawa Health Science Network Research Ethics Board. This study was performed at two tertiary care hospitals within The Ottawa Hospital network. Each of the two hospitals has its own 28-bed tertiary medical-surgical ICU, with 2500 combined ICU admissions per year. The Ottawa Hospital Network is a regional HCT and Oncology centre.

All data was obtained from the Ottawa Hospital Data Warehouse, a clinical and health administrative database that has been used in previous research [22, 37]. Quality of the gathered data is routinely confirmed through the use of regular quality-assurance checks.

We retrospectively evaluated patients with hematologic malignancies or HCT who were over the age of 18 and had undergone RRS activation at one of the participating hospitals between 2012 and 2016. Included patients were admitted under either the malignant hematology service or the HCT service, both of which admit patients with hematologic malignancies. We did not use specific exclusion criteria; however, patients were excluded if they did not meet the above inclusion criteria. “HCT patients” included all patients who had received at least one allogeneic or autologous HCT at any time prior to RRS activation. Patients were considered to be receiving active treatment if they were in the middle of a course of either chemotherapy or radiation therapy, regardless of cycle timing. For example, a patient who had completed a cycle of chemotherapy 2 weeks prior to RRS activation would qualify for inclusion if one or more cycles of chemotherapy remained within their course of treatment. Active treatment also included pre-HCT induction chemotherapy. Criteria for RRS activation at our institution have been published previously [38] and include respiratory distress, arrhythmia, and hypotension (Additional file 1: Table S1). However, all healthcare providers are encouraged to activate the RRS for any serious patient-related concerns. The RRS at our institution is comprised of a critical care nurse and respiratory therapist, each with several years of ICU experience, as well as 1–2 MDs. The
Descriptive statistics were utilized for between-group comparisons (with interquartile range, IQR), where indicated. Mean values (with standard deviation, SD), or as median IBM SPSS, Version 24.0). Data are presented as commercially available statistical packages (R, Version 3.3.3, and IBM SPSS, Version 24.0). Data are presented as mean values (with standard deviation, SD), or as medians (with interquartile range, IQR), where indicated. Descriptive statistics were utilized for between-group comparisons using Student’s t test (for normally distributed values), the Mann-Whitney test (for non-normally distributed values), and χ² (for categorical values). To evaluate predictors of mortality, a logistic regression model was created based on a priori selection of clinically important variables including patient demographics, medical comorbidities, and RRS activation characteristics. We adhered to an event per variable ratio > 10 [39] and intentionally avoided selection methods based on univariate testing in order to minimize potential overfitting [40].

Results
During the study period, the RRS was activated for 6132 patients. Of these, 401 patients met our inclusion criteria and were included in the analysis (Additional file 4: Figure S1). One hundred and forty-five patients (36.2%) had received HCT prior to RRS activation. The baseline characteristics of the included patients are summarized in Table 1. Leukemia was the most prevalent hematologic malignancy in our population (39.2%), followed by lymphoma (32.7%) and multiple myeloma (14.7%). Three hundred and forty-one patients (85.0%) were classified as having “full” goals of care, which allowed for cardiopulmonary resuscitation, intubation, and transfer to ICU.

The characteristics of the included RRS calls are detailed in Table 2. Two hundred and forty-six patients across the entire cohort (61.3%) and 70 patients (48.3%) in the HCT group were actively receiving treatment at the time of RRS activation. One hundred and fifty-four patients (38.4%) were neutropenic at the time of RRS activation, and the most common reason for RRS activation was respiratory distress (124 patients, 30.9%).

A total of 145 patients (45.0%) were transferred to the ICU after their RRS call, and the in-hospital mortality rate for all patients was 41.9% (Table 3). Within the HCT subgroup, 55 patients (41.7%) were transferred to the ICU and 53 patients (36.6%) died in hospital. There were no significant differences in mortality or need for ICU admission between the HCT and non-HCT groups (p ≥ 0.05 for both comparisons). The most common reason for RRS activation was respiratory distress, followed by dysrhythmias (Fig. 1). As a reason for activation, respiratory distress also accounted for the highest proportion of RRS calls that resulted in mortality (Fig. 1).

Among included patients, 318 (79.3%) met criteria for suspected infection, and the most common suspected source of infection was pulmonary (Table 4). The SIRS criteria had a sensitivity of 86.9% (95% CI 80.9–91.6) and a specificity of 38.2% (95% CI 31.9–44.8) for predicting in-hospital mortality. For the same population, the qSOFA criteria had a sensitivity of 61.9% (95% CI 54.1–
69.3) and a specificity of 91.4% (95% CI 87.1–94.7) for prediction of in-hospital mortality.

The results of the multivariate logistic regression analysis are presented in Additional file 3: Table S3. Factors that were independently associated with in-hospital mortality included ICU admission (OR 3.56, 95% CI 2.12–5.97), more than one RRS activation during admission (OR 2.45, 95% CI 1.63–3.69), goals of care that did not allow for cardiopulmonary resuscitation (OR 3.57, 95% CI 1.53–8.32), and goals of care that did not allow for ICU admission (OR 2.83, 95% CI 1.42–5.61). Factors that were associated with lower likelihood of in-hospital mortality included active malignancy treatment (OR 0.54, 95% CI 0.34–0.86) and longer length of hospital stay (OR 0.78, 95% CI 0.70–0.87).

Table 1 Baseline characteristics of hematologic oncology and subgroup of HCT patients

| Variables                              | All hematologic oncology patients (n = 401) | HCT patients (n = 145) |
|----------------------------------------|---------------------------------------------|------------------------|
| Age, years, mean (SD)                  | 61.6 (15.3)                                 | 53.1 (14.3)            |
| Male, n (%)                            | 254 (63.3)                                  | 88 (60.7)              |
| Hematologic diagnosis                  |                                             |                        |
| Leukemia                               | 157 (39.2)                                  | 82 (56.6)              |
| Lymphoma                               | 131 (32.7)                                  | 35 (24.1)              |
| Multiple myeloma                       | 60 (14.7)                                   | 10 (6.9)               |
| Other                                  | 53 (13.2)                                   | 18 (12.4)              |
| Admission source, n (%)                |                                             |                        |
| Home                                   | 341 (85.0)                                  | 123 (84.8)             |
| Acute care facility transfer           | 21 (5.2)                                    | 11 (7.6)               |
| Long-term care facility transfer       | 31 (7.7)                                    | 9 (6.2)                |
| Other                                  | 8 (2.0)                                     | 2 (1.4)                |
| Comorbidities, n (%)                   |                                             |                        |
| Congestive heart failure               | 43 (10.7)                                   | 6 (4.1)                |
| Arrhythmia                             | 66 (16.5)                                   | 28 (19.3)              |
| Valvular disease                       | 5 (1.2)                                     | 2 (1.4)                |
| Peripheral vascular disease            | 2 (0.5)                                     | 1 (0.7)                |
| Hypertension                           | 80 (20.0)                                   | 23 (15.9)              |
| Chronic obstructive pulmonary disease  | 30 (7.5)                                    | 8 (5.5)                |
| Diabetes mellitus                      | 129 (32.2)                                  | 45 (31.0)              |
| Renal failure                          | 26 (6.5)                                    | 4 (2.8)                |
| Liver disease                          | 17 (4.2)                                    | 10 (6.9)               |
| Metastatic cancer                      | 15 (3.7)                                    | 6 (4.1)                |
| Elixhauser comorbidity score, mean (SD)| 9.6 (8.2)                                   | 7.7 (6.6)              |
| Emergency department visits in past year, median (IQR) | 1 (0–2)                                   | 0 (0–1)                |
| Hospital admissions in the past year, median (IQR) | 1 (0–2)                                   | 1 (0–3)                |
| ICU admissions in the past year, median (IQR) | 0 (0–0)                                   | 0 (0–0)                |
| Limits of care, n (%)                  |                                             |                        |
| Full care                              | 300 (74.8)                                  | 126 (86.9)             |
| ICU-level care, no CPR                 | 22 (5.5)                                    | 4 (2.8)                |
| Do not resuscitate                     | 56 (14.0)                                   | 6 (4.1)                |
| Other/Unknown                          | 23 (5.7)                                    | 9 (6.2)                |

Table 2 Characteristics of initial RRS call in hematologic oncology and HCT patients

| Variables                              | All Hematologic oncology patients (n = 401) | HCT patients (n = 145) |
|----------------------------------------|---------------------------------------------|------------------------|
| Rapid response system activations during admission, median (IQR) | 1 (1–1)                                  | 1 (1–1)                |
| Time of initial RRS activation         |                                             |                        |
| Activations during working hours (0800–1659) | 190 (47.4)                              | 73 (50.3)              |
| Most recent vital signs                |                                             |                        |
| Systolic blood pressure, mmHg, mean (SD) | 118 (27)                                  | 120 (25)               |
| Diastolic blood pressure, mmHg, mean (SD) | 70 (15)                                   | 71 (15)                |
| Heart rate, beats/min, mean (SD)       | 108 (29)                                    | 112 (28)               |
| Temperature, degrees Celsius, mean (SD) | 37.0 (0.9)                                | 37.1 (0.8)             |
| Oxygen saturation, %, median (IQR)     | 95 (93–97)                                  | 95 (93–97)             |
| Most recent blood work                 |                                             |                        |
| White blood cell count, x10^9/L, median (IQR) | 4.7 (1.0–12.2)                          | 1.9 (0.1–8.3)          |
| Hemoglobin, g/L, mean (SD)             | 95 (19)                                     | 91 (17)                |
| Platelets, x10^9/L, mean (SD)          | 87 (102)                                    | 47 (65)                |
| Potassium, mmol/L, mean (SD)           | 4.0 (0.7)                                   | 3.9 (0.7)              |
| Creatinine, µmol/L, median (IQR)       | 83 (60–138)                                 | 76 (57–109)            |
| Urea, mmol/L, median (IQR)             | 7.4 (4.7–12.3)                             | 6.7 (4.3–10.9)         |
| Lactate, mmol/L, median (IQR)          | 2.0 (1.5–3.1)                              | 1.9 (1.5–3.2)          |
| Albumin, g/L, mean (SD)                | 24 (6)                                     | 24.2 (6.0)             |
| INR, median (IQR)                      | 1.3 (1.1–1.4)                              | 1.3 (1.1–1.4)          |
| Active treatment                       | 246 (61.3)                                 | 70 (48.3)              |
| Neutropenia                            | 154 (38.4)                                 | 70 (48.3)              |
| Time to first RRS activation from onset of concerning symptoms/signs < 1 h | 246 (61.3)                              | 81 (55.9)              |

Abbreviations: RRS rapid response system, SD standard deviation, IQR interquartile range, ICU intensive care unit
Discussion

The outcomes of hematologic oncology patients admitted to the ICU have been described previously [24–28]. However, very few previous studies have examined whether or not these outcome data can be extrapolated upstream of ICU admission to patients who deteriorate in-hospital. We have shown that hematologic oncology inpatients who require RRS activation experience high rates of ICU admission and mortality. Additionally, we have described the sensitivity and specificity of both the qSOFA and SIRS criteria with respect to prediction of in-hospital mortality for these patients. Finally, we have delineated several factors associated with increased risk of mortality in this population, which include ICU admission, more than one RRS activation, and goals of care that allow for fewer aggressive interventions. Few studies have previously examined these factors as they relate to the hematologic oncology population during RRS calls.

We found that hematologic oncology inpatients who experience RRS activation had an in-hospital mortality rate of 41.9%, which is higher than mortality among other previously studied RRS populations, including the elderly [37], general oncology patients [41], and surgical patients [42] (36.2%, 33%, and 28.4%, respectively). In our database, in-hospital mortality among non-hematologic oncology RRS patients was 29.9% [43], suggesting markedly higher mortality among the hematologic oncology population, as expected. This suggests that the hematologic oncology population is uniquely vulnerable, which may be due to the risk of infection and treatment-related complications in these patients, as described earlier.

Previous studies have examined mortality of hematologic oncology patients admitted to the ICU [26, 44]. Most recently, de Vries et al. [29] described a 28-day survival rate of 56% among hematologic oncology patients admitted to the ICU. Our data suggests that mortality after RRS activation is similar to mortality rates after ICU admission. This information may be of use to RRS clinicians, as prognostication of outcomes among these patients may begin upstream of ICU admission, at the time of assessment following deterioration. The high risk of mortality in this population emphasizes the need for health care providers to appropriately assess these patients using prognostic tools prior to making the decision to transfer to the ICU.

We describe several unique factors associated with in-hospital mortality in the hematologic oncology population after RRS activation, which add novel insights to the growing body of literature describing the outcomes and

| Outcomes                                | All hematologic oncology patients (n = 401) | HCT patients (n = 145) |
|-----------------------------------------|--------------------------------------------|------------------------|
| Mortality, n (%)                         | 168 (41.9)                                 | 53 (36.6)              |
| Admit to ICU, n (%)                      | 145 (45.0)                                 | 55 (41.7)              |
| ICU length of stay, days, median (IQR)   | 5 (1–9)                                    | 6 (2–9)                |
| Hospital length of stay, days, median (IQR) | 19 (8.5–37)                              | 26.5 (16–47)          |
| Survivors discharged home, n (%)         | 154 (76.2)                                 | 61 (77.2)              |

*aAnalysis only includes patients with goals of care allowing for ICU admission (hematology oncology: n = 322; HCT: n = 131)*

*bAnalysis only includes survivors initially from home (hematology oncology: n = 202; HCT: n = 79)*

Abbreviations: RRS rapid response system, ICU intensive care unit, IQR interquartile range, CI confidence interval
Table 4 Prognostic accuracy of sepsis criteria in hematology oncology and HCT patients with suspected infection

| Variables                                      | All hematology oncology patients (n = 318) | HCT patients (n = 122) |
|------------------------------------------------|------------------------------------------|------------------------|
| Suspected source of infection, n (%)           |                                          |                        |
| Pulmonary                                       | 151 (47.5)                               | 55 (45.1)              |
| Gastrointestinal                               | 89 (28.0)                                | 37 (30.3)              |
| Urinary tract                                   | 35 (11.0)                                | 13 (10.7)              |
| Skin/soft tissue                                | 10 (3.1)                                 | 4 (3.3)                |
| Central nervous system                          | 6 (1.9)                                  | 3 (2.5)                |
| Other/unknown                                   | 27 (8.5)                                 | 10 (8.2)               |
| Disease severity, median (IQR)                 |                                          |                        |
| Total SOFA score                                | 3 (1–5)                                  | 3 (2–5)                |
| Respiratory SOFA score                         | 1 (0–3)                                  | 1 (0–3)                |
| Coagulation SOFA score                         | 1 (0–1)                                  | 1 (1–2)                |
| Liver SOFA score                                | 0 (0–0)                                  | 0 (0–0)                |
| Cardiovascular SOFA score                      | 1 (1–3)                                  | 1 (1–3)                |
| Central nervous system SOFA score              | 0 (0–1)                                  | 0 (0–1)                |
| Renal SOFA score                                | 1 (0–2)                                  | 1 (0–2)                |
| SIRS criteria                                   |                                          |                        |
| Sensitivity, % (95% CI)                         | 86.9 (80.9–91.6)                         | 92.5 (81.8–97.9)       |
| Specificity, % (95% CI)                         | 38.2 (31.9–44.8)                         | 25.0 (16.6–35.1)       |
| Positive predictive value, % (95% CI)           | 50.3 (47.4–53.3)                         | 41.5 (38.2–44.5)       |
| Negative predictive value, % (95% CI)           | 80.2 (72.6–86.1)                         | 85.2 (67.8–94.0)       |
| Positive likelihood ratio (95% CI)              | 1.41 (1.25–1.58)                         | 1.23 (1.07–1.42)       |
| Negative likelihood ratio (95% CI)              | 0.34 (0.22–0.52)                         | 0.30 (0.11–0.83)       |
| qSOFA criteria                                  |                                          |                        |
| Sensitivity, % (95% CI)                         | 61.9 (54.1–69.3)                         | 64.2 (49.8–76.9)       |
| Specificity, % (95% CI)                         | 91.4 (87.1–94.7)                         | 88.0 (79.6–93.9)       |
| Positive predictive value, % (95% CI)           | 83.9 (77.1–88.9)                         | 75.6 (63.2–84.8)       |
| Negative predictive value, % (95% CI)           | 76.9 (73.2–80.2)                         | 81.0 (74.7–86.0)       |
| Positive likelihood ratio (95% CI)              | 7.21 (4.67–11.15)                        | 5.37 (2.97–9.68)       |
| Negative likelihood ratio (95% CI)              | 0.42 (0.34–0.51)                         | 0.41 (0.28–0.59)       |

Abbreviations: CI confidence interval, IQR interquartile range, SOFA Sequential Organ Failure Assessment

prognostic variables among this patient population [30]. Goals-of-care designations that allow for fewer aggressive interventions were associated with higher risk of mortality in our study. This is to be expected, given that these patients receive fewer life-sustaining therapies and tend to be palliated sooner than those who are admitted to the ICU and undergo mechanical ventilation and cardiopulmonary resuscitation [45].

ICU admission itself was also associated with increased mortality in our study. This is consistent with previous data comparing outcomes of ICU versus non-ICU hematologic oncology patients. Jacobson et al. [46] found that in a sample of 656 hematologic oncology patients, in-hospital mortality was 33% for patients admitted to the ICU, compared to 8% for those who were not. Long-term survival rates were also better in non-ICU patients in this study. This highlights the importance of appropriate triaging and decision-making for hematologic oncology ward patients who acutely deteriorate, as ICU admission should ideally only occur for those patients who can predictably benefit from it.

Our data show that compared with a single RRS activation, more than one RRS call for a given patient during a single admission is associated with increased mortality during the same admission. This is consistent with previous data demonstrating a relationship between increased number of RRS calls and higher risk of in-hospital mortality, after adjusting for patient factors [47, 48]. While there are few significant differences between patients with single versus multiple RRS calls [47], a higher number of RRS activations may reflect instability or frailty. Additionally, this may signify the need to use a lower ICU admission threshold for this vulnerable population, such that prolonged ward deterioration and subsequent negative outcomes may be avoided.

Azoulay et al. [27] previously demonstrated that hematologic oncology patients whose malignancies were in complete or partial remission were less likely to die in hospital after ICU admission. The same association was described for patients with solid tumors admitted to the ICU [49]. Although our data did not capture remission status of the included patients, we found that active malignancy treatment in the form of chemotherapy and/or radiation is associated with a lower risk of in-hospital mortality among hematologic oncology patients. Following ICU admission, ongoing chemotherapy has been associated with longer length of hospital and ICU stays, but mortality in these patients is similar to those who do not receive chemotherapy [50]. In our study, the association between active treatment and reduced mortality may be influenced by residual confounding, as those who receive active treatment may be healthier and may therefore experience more favorable outcomes following ICU admission. Nonetheless, these data may help RRS
clinicians with decision making, as it appears that those patients receiving active treatment at the time of deterioration may benefit from ICU admission and aggressive intervention.

As mentioned, the association between early versus late ICU admission and improved survival in hematologic oncology patients has been established previously. Though there is variability among the studies that have examined this association, rates of in-hospital mortality for early ICU-admitted hematologic oncology patients ranges from 20 to 65% [31, 32, 51]. Our reported mortality rate lies centrally within this range, and further studies are required to elucidate whether or not RRS activation can facilitate earlier ICU admission in this population, and therefore lead to improved outcomes.

One potential explanation for the benefits of early ICU admission is that deterioration and death in this population can occur in a dramatically rapid fashion as a result of the previously mentioned high-risk features in these patients such as immunosuppression [31, 33, 52]. This concept may also partly explain the association between longer hospital stay and lower risk of mortality in our study, as patients who experienced rapid deterioration and death, and therefore shorter length of hospital stay, may have represented a large proportion of those who died in hospital.

Infectious complications occur at high rates in the hematologic oncology population and are responsible for significant morbidity and mortality [17–19]. Our data confirm that infection is a major component of in-hospital deterioration of hematologic oncology patients, as 79.3% of the patients included in our study met criteria for suspected infection. The SIRS and qSOFA tools have been applied to other in-patient populations with suspected infection for risk stratification [22, 23, 53]; however, ours is the first study to examine their use in hematologic oncology patients.

We found that the SIRS criteria were more sensitive while the qSOFA criteria were more specific with respect to prognostic accuracy of in-hospital mortality for hematologic oncology patients with suspected infection. This is in keeping with recent data suggesting similar associations in patients with suspected infection who undergo RRS activation [22], as well as the observation that higher mortality rates are seen among ICU patients when Sepsis-3 criteria are applied, as compared with Sepsis-2 criteria [54]. It is important to note that in the general population, SIRS and qSOFA patients are not entirely similar, and each prognostic score must be evaluated in context. There appears to be a role for both the SIRS and qSOFA criteria in this population, and both scoring systems may be used in a complementary fashion. The value of the SIRS criteria in these patients lies in screening. For those who do meet SIRS criteria, however, the qSOFA criteria should then be used for risk stratification upstream of ICU admission, given their high specificity with respect to in-hospital death. This is especially important given the previously mentioned observation that appropriately selected hematologic oncology patients who are admitted to ICU early may experience lower mortality rates.

This study has several strengths. We used a previously validated database that includes data from two hospitals within a single hospital network. Additionally, this is one of few studies to examine outcomes of hematologic oncology patients in the context of RRS activation. The study’s limitations include lack of access to data that would identify the impact of RRS activation on goals-of-care designation. It is therefore unclear if RRS activation significantly influences medical directive changes and subsequently rates of mortality in this population. Additionally, the criteria used to trigger RRS calls at our institution may lead to delays in the detection of specific clinical entities such as sepsis, as compared with other triggering criteria such as the qSOFA or National Early Warning (NEWS) scores. Finally, the ability to include HCT in the multivariate analysis was hindered by sample size. Though there was no difference in mortality between HCT and non-HCT patients in our study, historically allogenic HCT in particular has been described as a prognostic factor for poor outcomes in hematologic oncology patients admitted to ICU [55]. More data is required to adequately describe the potential prognostic significance of HCT in this population. With respect to other prognostic factors, further research should focus on the interplay between active treatment and disease remission status as related to in-hospital mortality, as well as the role of disposition and goals-of-care planning for patients who are denied ICU admission after RRS calls. Further validation of our described prognostic variables, as well as further investigation into potential residual confounders, would be useful in the development of decision rules for this population.

Conclusions

We found that hematologic oncology patients who are admitted to hospital and suffer acute deterioration experience high rates of ICU admission and in-hospital mortality. Factors associated with increased hospital mortality include ICU admission and increased number of RRS activations, while factors associated with improved survival include active malignancy treatment and longer hospital length of stay. For most of these patients, respiratory distress is the defining feature of their decompensation, and many are neutropenic at the time of RRS activation. Finally, among the subset of these patients with suspected infection, SIRS criteria are more sensitive while qSOFA criteria are more specific with respect to prognostic accuracy of in-hospital mortality.
Additional files

**Additional file 1:** Table S1. Rapid Response System criteria at The Ottawa Hospital. (DOCX 14 kb)

**Additional file 2:** Table S2. Systemic Inflammatory Response Syndrome (SIRS) Criteria. (DOCX 13 kb)

**Additional file 3:** Table S3. Multivariable logistic regression model for prediction of mortality among Hematologic Oncology patients requiring RRS activation. (DOCX 14 kb)

**Additional file 4:** Figure S1. Patients receiving RRS activation at The Ottawa Hospital from 2012 to 2016 (DOCX 24 kb)

Abbreviations

ED: Emergency department; HCT: Hematopoietic cell transplant; ICU: Intensive care unit; IQR: Interquartile range; cSOFa: quick Sequential Organ Failure Assessment; RRS: Rapid response system; SD: Standard deviation; SIRS: Systemic Inflammatory Response Syndrome

Acknowledgements

Not applicable.

Authors’ contributions

BG, SMF, and KK designed the study. BG, SMF, PMR, PT, and KK gathered the data. SMF, AT, and KK analyzed the data. All authors interpreted the analyzed data. All authors wrote the manuscript and revised the manuscript for content. All authors agree to be responsible for study contents.

Funding

None to report.

Availability of data and materials

The datasets generated and analyzed are not publicly available due to patient privacy considerations, but are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Ethics approval for this study was obtained from the Ottawa Health Sciences Network Research Ethics Board.

Consent for publication

Not applicable.

Competing interests

Dr. Andrew J. E. Seely holds patents related to multiorgan variability analysis and has shares in Therapeutic Monitoring Systems Inc. The other authors declare that they have no competing interests.

Author details

1. Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
2. Department of Emergency Medicine, University of Ottawa, Ottawa, ON, Canada.
3. School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
4. Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
5. Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
6. Department of Medicine, Division of Critical Care, McMaster University, Hamilton, ON, Canada.
7. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
8. Department of Medicine, Sinai Health System, and Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.
9. Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
10. Department of Anesthesiology and Pain Medicine, University of Ottawa, Ottawa, ON, Canada.
11. Division of Palliative Care, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
12. Institut du Savoir Montfort, Ottawa, ON, Canada.
13. The Ottawa Hospital, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.

Received: 23 April 2019 Accepted: 13 August 2019
Published online: 27 August 2019

References

1. Yeo CD, Kim JW, Kim SC, Kim YK, Kim KH, Kim HJ, et al. Prognostic factors in critically ill patients with hematologic malignancies admitted to the intensive care unit. J Crit Care. 2012;27(6):379.e1–6.
2. Guven GS, Uzun O, Cakir B, Akova M, Unal S. Infectious complications in patients with hematologic malignancies consulted by the infectious diseases team: a retrospective cohort study (1997-2001). Support Care Cancer. 2006;14(1):52–5.
3. Franchini M, Frattini F, Crestani S, Bonfant C. Bleeding complications in patients with hematologic malignancies. Semin Thromb Hemost. 2003;3:94–100.
4. Porcu P, Cripe LD, Ng EW, Bhata S, Danielson CW, Orazi A, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000;39:1–211–18.
5. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–54.
6. Jones DA, DeVita MA, Bellomo R. Rapid-response teams. N Engl J Med. 2011;365(2):139–46.
7. Chan PS, Khalid A, Longmore LS, Berg RA, Kosiborod M, Spertus JA. Hospital-wide code rates and mortality before and after implementation of a rapid response team. JAMA. 2008;300(21):2506–13.
8. Jacques T, Harrison GA, Mclaws ML. Attitudes towards and evaluation of medical emergency teams: a survey of trainees in intensive care medicine. Anaesth Intensive Care. 2008;36(1):90–5.
9. Chan PS, Jain R, Nallmothu BK, Berg RA, Sasson C. Rapid response teams: a systematic review and meta-analysis. Arch Intern Med. 2010;170(1):18–26.
10. Winters BD, Weaver SJ, Pthoh ER, Yang T, Pham JC, Dey SM. Rapid-response systems as a patient safety strategy: a systematic review. Ann Intern Med. 2013;158(5 Pt 2):417–25.
11. Maharaj R, Raffaele I, Wendon J. Rapid response systems: a systematic review and meta-analysis. Crit Care. 2015;19:254.
12. Jones D, Bellomo R, Bates S, Warrillow S, Goldsmith D, Hart G, et al. Long-term effect of a medical emergency team on cardiac arrests in a teaching hospital. Crit Care. 2005;9(6):R808–15.
13. De Jong A, Jung B, Daurat A, Chauques G, Mahul M, Monnin M, et al. Effect of rapid response systems on hospital mortality: a systematic review and meta-analysis. Intensive Care Med. 2016;42(4):615–7.
14. Harrison DA, Gao H, Welch CA, Rowan KM. The effects of critical care outreach services before and after critical care: a matched-cohort analysis. J Crit Care. 2010;25(2):196–204.
15. Jones D, Moran J, Winters B, Welch J. The rapid response system and end-of-life care. Curr Opin Crit Care. 2013;19(6):616–23.
16. Ball C, Kirkby M, Williams S. Effect of the critical care outreach team on patient survival to discharge from hospital and readmission to critical care: non-randomised population based study. BMJ. 2003;327(7422):1014.
17. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia. Cancer. 2004;100(2):228–37.
18. Burutaran MB, Guadagna R, Grille S, Stevenazzi M, Guillermo C, Diaz L, et al. Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in Uruguay. Rev Bras Hematol Hemonc. 2015;37(1):28–33.
19. Engelhart S, Glasmacher A, Exner M, Klauser MH. Surveillance for nosocomial infections and fever of unknown origin among adult hematology-oncology patients. Infect Control Hosp Epidemiol. 2002;23(5):244–8.
20. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. CHEST. 1992;101(6):1644–55.
21. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):184–93.
22. De Jong A, van der Does E, Reardon PM, Schoonhoven L, Vroom M, et al. Comparison of cSOFa and SIRS for predicting adverse outcomes of patients with suspicion of sepsis outside the intensive care unit. Curr Care. 2017;21(1):73.
23. Finkielstein EJ, Jones DS, Ma KC, Pabon MA, Delgado T, Nakahara K, et al. Comparison of cSOFa and SIRS for predicting adverse outcomes of patients with suspicion of sepsis outside the intensive care unit. Curr Care. 2017;21(1):73.
24. Soubani AO, Heyland DK, Klein JL, Khansandani G, Ahmed HP, et al. Outcome and prognostic factors of hematopoietic stem cell transplantation recipients admitted to a medical ICU. Chest. 2004;126(5):1604–11.
25. Pène F, Aubron C, Azoulay E, Brot F, Thyén G, Rynard B, et al. Outcome of critically ill allogeneic hematopoietic stem-cell transplantation recipients: a reappraisal of indications for organ failure supports. J Clin Oncol. 2006;24(4):643–9.

26. Bird GT, Fanquhar-Smith P, Wignmore T, Porter M, Gruber PC. Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study. Br J Anaesth. 2012;108(3):452–62.

27. Azoulay E, Mokart D, Pène F, Lambert J, Krouacht A, Mayaux J, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique study. J Clin Oncol. 2013;31(22):2810–8.

28. Paralah S, Piggin A, Neeman T, Mitchell I, Crispin P, Davis A. Outcomes of haematology/oncology patients admitted to intensive care unit at the Canberra hospital. Intern Med. J. 2014;44(11):1087–94.

29. de Vries VA, Müller MCA, Arbous MS, Biemond BJ, Blijlevens NMA, Kusadasi N, et al. Long-term outcome of patients with a hematologic malignancy and multiple organ failure admitted at the intensive care. Crit Care Med2018 12,Online First. Available from: https://journals.lww.com/ccmjournal/Abstract/onlinefirst/Long_Term_Outcome_of_Patients_With_a_Hematologic-Malignancy.aspx. [cited 2018 Nov 13]

30. Taheri L, Anandanadesan R, de Lavallade H, Pagkalidou E, Pagliuca A, Mufti G, et al. The role of a critical care outreach service in the management of patients with haematological malignancy. J Intensive Care Soc. 2019;10:175114371985515.

31. Azoulay E, Pène F, Darmon M, Lengliné E, Benoit D, Soares M, et al. Managing critically ill hematology patients: time to think differently. Blood. Rev. 2015;29(6):359–67.

32. Lengliné E, Rauffez E, Lemiale V, Darmon M, Canet E, Bissel N, et al. Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure. Leuk Lymphoma. 2012;53(7):1352–9.

33. Song J-U, Suh GY, Park HY, Han SG, Kang YR, et al. Early intervention on the outcomes in critically ill cancer patients admitted to intensive care units. Intensive Care Med. 2012;38(9):1505–13.

34. Bokhari SW, Munir T, Memon S, Byrne JL, Russell NH, Bedd M. Impact of critical care reconfiguration and track-and-trigger outreach team intervention on outcomes of haematology patients requiring intensive care admission. Ann Hematol. 2010;89(5):505–12.

35. Hayano O, Al-Behany A, Zarychanski R, Chou A, Kharaba A, Baxter A, et al. Impact of critical care outreach on hematology/oncology stem cell transplant recipients: a cohort study. Bone Marrow Transplant. 2011;46(8):1384–44.

36. Kim W-Y, Hong S-B, Chang YJ, Park T, Seo H, Choi SH, et al. Medical emergency team, changing survival in patients with hematopoietic malignancies. Intensive Care Med. 2010;36:5165.

37. Fernando SM, Reardon PM, Midisaac DJ, Eagles D, Murphy K, Tanuseputro P, et al. Outcomes of older hospitalized patients requiring rapid response team activation for acute deterioration. Crit Care Med. 2018;46(12):1953–60.

38. Baxter AD, Cardinal P, Hooper J, Patel R. Medical emergency teams at the Ottawa Hospital: the first two years. Can J Anaesth. 2008;55(4):223–30.

39. Bokhari SW, Munir T, Memor S, Byrne JL, Russell NH, Bedd M. Impact of critical care reconfiguration and track-and-trigger outreach team intervention on outcomes of haematology patients requiring intensive care admission. Ann Hematol. 2010;89(5):505–12.

40. Hayano O, Al-Behany A, Zarychanski R, Chou A, Kharaba A, Baxter A, et al. Impact of critical care outreach on hematology/oncology stem cell transplant recipients: a cohort study. Bone Marrow Transplant. 2011;46(8):1384–44.

41. Kim W-Y, Hong S-B, Chang YJ, Park T, Seo H, Choi SH, et al. Medical emergency team, changing survival in patients with hematopoietic malignancies. Intensive Care Med. 2010;36:5165.

42. Fernando SM, Reardon PM, Midisaac DJ, Eagles D, Murphy K, Tanuseputro P, et al. Outcomes of older hospitalized patients requiring rapid response team activation for acute deterioration. Crit Care Med. 2018;46(12):1953–60.

43. Baxter AD, Cardinal P, Hooper J, Patel R. Medical emergency teams at the Ottawa Hospital: the first two years. Can J Anaesth. 2008;55(4):223–31.

44. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373–9.

45. Boyer E, Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer-Verlag; 2009. (Statistics for Biology and Health). Available from: //www.springer.com/gp/book/97803877772431. [cited 2018 Dec 5].

46. Austin CA, Hanzerker C, Stafford R, Mayer C, Culp L, Lin F-C, et al. Utilization of rapid response resources and outcomes in a comprehensive cancer center*. Crit Care Med. 2014;42(6):905–9.

47. Barocas DA, Kuhallahi CS, Ehrenfeld JM, Kapu AN, Penson DF, You CC, et al. Benchmarking the use of a rapid response team by surgical services at a tertiary care hospital. J Am Coll Surg. 2014;218(1):66–72.

48. Fernando SM, Reardon PM, Bagshaw SM, Scales DC, Murphy K, Tanuseputro P, et al. Impact of nighttime rapid response team activation on outcomes of hospitalized patients with acute deterioration. Crit Care. 2018;22(1):57.

49. Cornish M, Butler MB, Green RS. Predictors of poor outcomes in critically ill adults with hematologic malignancy. Can Respir J. 2016;2016:0431385.

50. Cassel JB, Jones AB, Meier DE, Smith TJ, Spragens LH, Weissman D. Hospital mortality rates: how is palliative care taken into account? J Pain Symptom Manag. 2010;40(6):914–25.